Mitomic™ Prostate Test
Mitomic™ Prostate Test (MPT™) – the answer to more accurate prostate cancer testing is here. MPT™ is a liquid biopsy prostate cancer test with 100 % negative predictive value.
Allgemein
Mitomic™ Prostate Test (MPT™) is a quantitative in vitro diagnostic test for the detection of the 3.4 kb mitochondrial DNA deletion and the 18S rRNA nuclear DNA sequence in human plasma. This liquid biopsy test is used to determine indication for a prostate biopsy in men 45 years and older with a Prostate Specific Antigen (PSA) concentration <10 ng/ml with suspected prostate cancer. MPT™ can also detect clinically significant cancers that are PSA negative (below 4ng/ml).
MPT™ is independent of PSA, age, family history or the use of 5-ARI inhibitors. The test is a simple laboratory assay with a real-time PCR following a standard DNA extraction. Result interpretation is straightforward and based on clinically validated cut-off values.
Mitomic™ Prostate Test provides you with
- Simple, blood-based test
- NPV 100 %: safely avoid a biopsy
- Sensitivity 92 %
- Accurate yes/no result, no algorithm
Technische Daten
| Products available |
|
| Use | For in vitro diagnostic use |
| Method | Real-time PCR |
| Sample type | Plasma |
| Storage | -30°C … -15°C, dark |
| Additionally needed | Validated real-time PCR instruments include QuantStudio™ 5 Real-Time PCR System and Applied Biosystems® 7500 Fast as well as 7500 Real-Time PCR System. |
Weitere Informationen
More information available: www.mdnalifesciences.com/mitomic-tests